|
SEC
File Number: 0-54296
|
|
CUSIP
Number: 05463V 100
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check one):
[X]
Form 10-K [ ] Form 20-F [ ] Form 11-K [
] Form 10-Q [ ] Form 10-D [ ]
Form N-SAR
For
Period Ended: December 31, 2020
|
[
]
|
Transition Report on
Form 10-K
|
|
[
]
|
Transition Report on
Form 20-F
|
|
[
]
|
Transition Report on
Form 11-K
|
|
[
]
|
Transition Report on
Form 10-Q
|
|
[
]
|
Transition Report on
Form N-SAR
|
For
the Transition Period Ended: _______________
|
Read Instruction (on back page) Before Preparing Form. Please
Print or Type.
Nothing in this form shall be construed to imply that the
Commission has verified any information contained herein.
|
|
If
the notification relates to a portion of the filing checked above,
identify the item(s) to which the notification relates:
|
|
|
|
|
PART I - REGISTRANT INFORMATION
|
Full Name of
Registrant:
|
Axim
Biotechnologies, Inc.
|
|
Former Name if
Applicable:
|
|
|
Address of Principal
Executive Office (Street and Number):
|
6191 Cornerstone
Court, E., Suite 114
|
|
City, State and Zip
Code:
|
San Diego, CA
92121
|
PART II - RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort
or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if
appropriate)
|
|
(a)
|
The
reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
|
|
[X]
|
(b)
|
The
subject annual report, semi-annual report, transition report on
Forms 10-K, 20-F, 11-K, Form N-SAR, or Form N-CSR or portion
thereof, will be filed on or before the 15th calendar day following
the prescribed due date; or the subject quarterly report or
transition report on Form 10-Q, or portion thereof, will be filed
on or before the fifth calendar day following the prescribed due
date; and
|
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
|
PART III - NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 11-K, 10-Q,
10-D, N-SAR, N-CSR or the transition report portion thereof, could
not be filed within the prescribed time period.
The Company is unable to file, without unreasonable effort or
expense, its Annual Report on Form 10-K for the period ending
December 31, 2020 (the “Form 10-K”). Additional time is needed for
the Company’s independent registered public accounting firm to
complete its review of the unaudited financial statements included
in the Form 10-K and for the Company to provide additional
information to its accountants and auditors in order to produce a
complete, accurate Annual Report. Additionally, the Company seeks
an extension to finalize the narrative of the Form 10-K so that it
will properly inform investors and the public of the Company’s
actions in the 2020 fiscal year. The Company anticipates on filing
its Form 10-K on or by April 15, 2021.
PART IV - OTHER INFORMATION
(1)Name
and telephone number of person to contact in regard to this
notification:
|
John W. Huemoeller II
|
|
(212) 332-1677
|
|
(Name)
|
|
(Area
Code) (Telephone number)
|
(2)Have
all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months (or for such
shorter) period that the registrant was required to file such
reports) been filed? If answer is no, identify report(s):
[X] Yes [ ] No
(3)Is
it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject
report or portion thereof:
[ ] Yes [X] No
If
so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the
reasons why a reasonable estimate of the results cannot be
made.
|
AXIM Biotechnologies, Inc.
|
|
(Name
of Registrant as Specified in Charter)
|
has
caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Date:
March 30, 2021
|
/s/ John W.
Huemoeller II
|
|
|
John W. Huemoeller
II President
|
INSTRUCTION: The form may be signed by an executive officer of the
registrant or by any other duly authorized representative. The name
and title of the person signing the form shall be typed or printed
beneath the signature. If the statement is signed on behalf of the
registrant by an authorized representative (other than an executive
officer), evidence of the representative’s authority to sign on
behalf of the registrant shall be filed with the form.